Company profile
Illumina, Inc.
NASDAQ: ILMN · Healthcare · Medical - Diagnostics & Research
#66 of 1,418 Healthcare companies by revenue40th-percentile growth
EA Score
84B+FH 92DQ 85GM 52SS 92
v0.1 · 65/100 weight · provisional
↑ market scale, disclosure history · ↓ 3-yr revenue growth, revenue growth (YoY)
Methodology →Revenue TTM
$4.4B
Rev growth YoY (TTM)
+1.2%
Net income (FY)
$850.0M
Employees
8,600
as of 2026-08-05
Market cap
$30.7B
as of 2026-08-05
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$4.3B$4.3B2025
Net income$850.0M$850.0M2025
Operating income$807.0M$807.0M2025
Total assets$6.6B$6.6B2025
Equity$2.7B$2.7B2025
Revenue trend
FY2019 – FY2025 · USD
FY19
FY19
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2025
By product
Sequencing92%
Microarray8%
By geography
Americas55%
EMEA29%
Asia Pacific10%
CHINA6%
The read
What is Illumina, Inc.’s revenue?
Illumina, Inc. booked $4.3B in FY2025 revenue, contracting 0.7% year over year — about the middle of the pack among Healthcare companies we track, at a 19.6% net margin.
Peers · Healthcare
The Ensign Group, Inc.80B+Elanco Animal Health Incorporated66BDexCom, Inc.87AIDEXX Laboratories, Inc.88AThe Cooper Companies, Inc.86AAlign Technology, Inc.83B+Neighbors
San Diego →Key facts
CEOJacob Thaysen
SectorHealthcare
IndustryMedical - Diagnostics & Research
HeadquartersSan Diego, CA
ExchangeNASDAQ: ILMN
Employees8,600
IPO date2000-07-28
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.